{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:05:46Z","timestamp":1789725946425,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"CARING"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tuberculous meningitis is a devastating manifestation of tuberculosis, disproportionately affecting children and persons with HIV. Despite decades of clinical experience, diagnosis is often delayed and outcomes remain poor. At the US\u2013Mexico border, management is further complicated by the high prevalence of Mycobacterium bovis, a member of the Mycobacterium tuberculosis complex intrinsically resistant to pyrazinamide, one of the few first-line agents with reliable central nervous system penetration. We present a case of M. bovis meningitis in a patient residing near the US\u2013Mexico border, highlighting the diagnostic and therapeutic challenges posed by intrinsic pyrazinamide resistance. Drawing from this case, we review evidence supporting the early use of adjunctive CNS-penetrative antimicrobials during suspected tuberculosis meningitis in regions where M. bovis is endemic.<\/jats:p>","DOI":"10.1093\/ofid\/ofag384","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:38:47Z","timestamp":1788521927000},"source":"Crossref","is-referenced-by-count":0,"title":["Management of\n                    <i>Mycobacterium bovis<\/i>\n                    Meningitis: The Case for Adjunctive Empirical Therapy"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8363-322X","authenticated-orcid":false,"given":"Morgan","family":"Birabaharan","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California , San Diego, La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7964-6220","authenticated-orcid":false,"given":"Annie N","family":"Cowell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California , San Diego, La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2026091805313777900_ofag384-B1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","article-title":"Tuberculous meningitis","volume":"13","author":"Wilkinson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"2026091805313777900_ofag384-B2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.5588\/ijtld.21.0159","article-title":"Clinical outcomes among patients with tuberculous meningitis receiving intensified treatment regimens","volume":"25","author":"Smith","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026091805313777900_ofag384-B3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/cid\/ciw763","article-title":"Long-term mortality of patients with tuberculous meningitis in New York City: a cohort study","volume":"64","author":"Vinnard","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026091805313777900_ofag384-B4","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1128\/AAC.00319-12","article-title":"Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis","volume":"56","author":"Tho","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805313777900_ofag384-B5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1054\/tube.2000.0263","article-title":"Mycobacterium bovis infection in human beings","volume":"81","author":"Grange","year":"2001","journal-title":"Tuberculosis"},{"key":"2026091805313777900_ofag384-B6","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.1982.03320410052032","article-title":"Mycobacterium bovis meningitis","volume":"247","author":"Jones","year":"1982","journal-title":"JAMA"},{"key":"2026091805313777900_ofag384-B7","doi-asserted-by":"crossref","first-page":"ofaa475","DOI":"10.1093\/ofid\/ofaa475","article-title":"Disseminated Mycobacterium bovis infection complicated by meningitis and stroke: a case report","volume":"7","author":"Clifford","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026091805313777900_ofag384-B8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/pgmj.62.729.653","article-title":"Tuberculous meningitis due to Mycobacterium bovis: a report of two cases","volume":"62","author":"Wilkins","year":"1986","journal-title":"Postgrad Med J"},{"key":"2026091805313777900_ofag384-B9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF02310361","article-title":"A case of disseminated Mycobacterium bovis infection in an AIDS patient","volume":"14","author":"Albrecht","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026091805313777900_ofag384-B10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/cid\/ciw371","article-title":"Human Tuberculosis caused by Mycobacterium bovis in the United States, 2006-2013","volume":"63","author":"Scott","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026091805313777900_ofag384-B11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3201\/eid1406.071485","article-title":"Tuberculosis from Mycobacterium bovis in binational communities, United States","volume":"14","author":"Rodwell","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"2026091805313777900_ofag384-B12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1086\/657118","article-title":"Tuberculosis due to Mycobacterium bovis in patients coinfected with human immunodeficiency virus","volume":"51","author":"Park","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026091805313777900_ofag384-B13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41590-018-0119-x","article-title":"NIH tuberculous meningitis writing group. Tuberculous meningitis: a roadmap for advancing basic and translational research","volume":"19","author":"Jain","year":"2018","journal-title":"Nat Immunol"},{"key":"2026091805313777900_ofag384-B14","first-page":"798764","article-title":"Tuberculous meningitis: diagnosis and treatment overview","volume":"2011","author":"Marx","year":"2011","journal-title":"Tuberc Res Treat"},{"key":"2026091805313777900_ofag384-B15","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/S1473-3099(25)00364-0","article-title":"A clinical practice guideline for tuberculous meningitis","volume":"26","author":"Donovan","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"2026091805313777900_ofag384-B16","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4081\/ni.2011.e9","article-title":"Importance of differentiating Mycobaterium bovis in tuberculous meningitis","volume":"3","author":"Gonz\u00e1lez-Duarte","year":"2011","journal-title":"Neurol Int"},{"key":"2026091805313777900_ofag384-B17","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/AAC.00064-11","article-title":"Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis","volume":"55","author":"Thwaites","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805313777900_ofag384-B18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","article-title":"Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial","volume":"13","author":"Ruslami","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2026091805313777900_ofag384-B19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified antituberculosis therapy in adults with tuberculous meningitis","volume":"374","author":"Heemskerk","year":"2016","journal-title":"N Engl J Med"},{"key":"2026091805313777900_ofag384-B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tube.2016.01.004","article-title":"Safety and efficacy of additional levofloxacin in tuberculous meningitis: a randomized controlled pilot study","volume":"98","author":"Kalita","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"2026091805313777900_ofag384-B21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14740338.2013.796362","article-title":"Risks associated with the therapeutic use of fluoroquinolones","volume":"12","author":"Stahlmann","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"2026091805313777900_ofag384-B22","volume-title":"WHO Consolidated guidelines on tuberculosis. Module 4: treatment \u2013 drug-resistant tuberculosis treatment (2022 update) [guideline]","author":"World Health Organization","year":"2022"},{"key":"2026091805313777900_ofag384-B23","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1128\/AAC.02784-14","article-title":"Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis","volume":"58","author":"Sun","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805313777900_ofag384-B24","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/INF.0000000000001114","article-title":"Linezolid is associated with improved early outcomes of childhood tuberculous meningitis","volume":"35","author":"Li","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2026091805313777900_ofag384-B25","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1038\/s41467-022-35730-3","article-title":"Dynamic 18F-pretomanid PET imaging in animal models of TB meningitis and human studies","volume":"13","author":"Mota","year":"2022","journal-title":"Nat Commun"},{"key":"2026091805313777900_ofag384-B26","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1038\/s41467-024-50989-4","article-title":"Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"2026091805313777900_ofag384-B27","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/cid\/ciab992","article-title":"Cycloserine and linezolid for tuberculosis meningitis: pharmacokinetic evidence of potential usefulness","volume":"75","author":"Kempker","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026091805313777900_ofag384-B28","doi-asserted-by":"crossref","first-page":"e0315999","DOI":"10.1371\/journal.pone.0315999","article-title":"Pharmacometabolomics in TB meningitis-understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid","volume":"20","author":"Collins","year":"2025","journal-title":"PLoS One"},{"key":"2026091805313777900_ofag384-B29","doi-asserted-by":"crossref","first-page":"e0093125","DOI":"10.1128\/aac.00931-25","article-title":"Cerebrospinal fluid penetration of cycloserine\/terizidone and clofazimine in patients with pulmonary TB","volume":"69","author":"Upton","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091805313777900_ofag384-B30","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1186\/s12879-025-12052-5","article-title":"Plasma and CSF pharmacokinetic characteristics of second-line anti-tuberculosis drugs in a patient with multidrug-resistant tuberculous meningitis","volume":"25","author":"Gao","year":"2025","journal-title":"BMC Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag384\/71121810\/ofag384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/9\/ofag384\/71121810\/ofag384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:32:01Z","timestamp":1789723921000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag384\/8801939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag384","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"ofag384"}}